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Abstract: Background. For patients with advanced laryn-
geal cancer, a trial was designed to determine if chemother-
apy alone, in patients achieving a complete histologic
complete response after a single neoadjuvant cycle, was an
effective treatment with less morbidity than concurrent
chemoradiotherapy.
Methods. Thirty-two patients with advanced laryngeal or
hypopharyngeal cancer received 1 cycle of induction chemo-
therapy, and subsequent treatment was decided based on
response.
Results. A histologic complete response was achieved in 4
patients and were treated with chemotherapy alone. All 4
patients’ cancer relapsed in the neck and required surgery
and postoperative radiotherapy (RT). Twenty-five patients were
treated with concomitant chemoradiation. Three patients were
treated with surgery. Overall survival and disease-specific sur-
vival at 3 years were 68% and 78%, respectively.
Conclusion. Chemotherapy alone is not feasible for long-
term control of regional disease in patients with advanced la-
ryngeal cancer even when they achieve a histologic complete
response at the primary site. VC 2009 Wiley Periodicals, Inc.
Head Neck 32: 1040–1047, 2010
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The introduction of chemotherapy as part of
organ-preservation strategies for treatment of
advanced squamous cell carcinoma of the larynx
has led to continuous refinement of the relative
roles and timing of chemotherapy, radiotherapy
(RT), and surgery in treatment. Chemoradiation
approaches have been unsuccessful at improving
overall survival compared with primary sur-
gery1; however, tumor response to induction
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chemotherapy has been predictive of patients
with a favorable response to chemoradiotherapy.
In these protocols, the highest survival rates were
seen in patients experiencing a complete tumor
response after 1 or 2 cycles of chemotherapy.1,2
Organ-preservation chemoradiation protocols
continue to have a high level of associated mor-
bidity. The addition of intensive chemotherapy
to RT produces higher levels of mucositis. The
long-term effects of RT that include significant
fibrosis with resulting speech and swallowing
dysfunction appear greater after concurrent che-
moradiation compared with radiation alone.3
Treatment of advanced laryngeal cancer with
chemotherapy alone in patients with highly che-
mosensitive tumors would potentially result in
improved voice and swallowing outcomes by
avoiding both acute and late effects of radiation.
Hence, based on the favorable prognosis associ-
ated with a complete response at the primary
site, we designed a single-arm phase II study to
determine if advanced tumors of the larynx,
which completely respond to a single cycle of
induction chemotherapy, could be managed with
a chemotherapy-only approach.
MATERIALS AND METHODS
Eligibility. All patients had histologically con-
firmed, previously untreated, stage III or stage
IVA squamous cell carcinoma of the larynx or
hypopharynx. Patients underwent pretreatment
endoscopic tumor staging, contrast-enhanced CT
scanning, and tissue biopsy. Patients were
required to have an Eastern Cooperative Oncol-
ogy Group (ECOG) performance score <3 and
laboratory testing documenting eligibility for
chemotherapy. This protocol was approved by
the Institutional Review Board at the Univer-
sity of Michigan, and all patients gave docu-
mented informed consent. The study schema is
shown in Figure 1.
Induction Chemotherapy. Prior to enrollment,
patients underwent a history and physical ex-
amination, complete blood count with differen-
tial and platelets and serum chemistries. For
patients with a creatinine clearance 60 cc/mi-
nute and hearing loss 30 dB between 500 and
2000 Hz, cisplatin (100 mg/m2) was adminis-
tered on day 1. Those with a creatinine clear-
ance of 30 to 59 cc/minute or hearing loss >30
dB received carboplatin (AUC ¼ 6) on day 1. In
addition, 5-fluorouracil (1000 mg/m2/day) was
administered by continuous infusion over 5
days.
Tumor Assessment. Bi-dimensional measure-
ments and biopsies of the primary tumor were
performed by direct laryngoscopy under anes-
thesia pretreatment and 3 weeks after induction
chemotherapy (IC). RECIST criteria were not
used,4 as repeat CT imaging was not used to
assess treatment response, nor was positron
emission tomography imaging. A final tumor
assessment under anesthesia was performed 8
weeks after completion of definitive chemoradia-
tion or definitive chemotherapy (cycles 2–4). If
persistent residual disease was detected at the
primary site or if a planned neck dissection was
necessary, the appropriate salvage surgery was
performed. Patients treated with chemotherapy
alone or chemoradiation who were disease-free,
went on to receive 2 additional cycles of adju-
vant chemotherapy as detailed below.
Chemotherapy Alone. Patients who were com-
plete clinical and histologic responders at the
primary site after IC, were treated with 3 addi-
tional alternating cycles of chemotherapy. Cycles
2 and 4 consisted of cisplatin (100 mg/m2) or
carboplatin (AUC ¼ 6) plus 5-fluorouracil (1000
mg/m2/day  5 days). Cycle 3 consisted of
weekly docetaxel (35 mg/m2  3 weeks) followed
by 1 week of rest. Patients with sustained com-
plete histologic response 8 weeks after these ini-
tial 4 cycles of chemotherapy, received an
additional 4 cycles of chemotherapy. Cycles 5
FIGURE 1. Study design.
Larynx Preservation in Advanced Laryngeal Cancer HEAD & NECK—DOI 10.1002/hed August 2010 1041
and 7 consisted of weekly docetaxel for 3 weeks
alternating with cisplatin (or carboplatin) and 5-
fluorouracil for cycles 6 and 8. Patients with bi-
opsy-proven disease at the primary site 8 weeks
after completion of the initial 4 cycles of chemo-
therapy underwent salvage total laryngectomy.
Neck evaluation was also performed and posi-
tive disease was an indication for neck dissec-
tion. Patients who had multiple positive nodes
or extracapsular spread were eligible for postop-
erative conventional RT or concurrent cisplatin
(or carboplatin) and RT treatment at the discre-
tion of the treatment team with conventional
fractionation (2.0 Gy per fraction, 5 fractions
per week). The dose to the tumor bed and lymph
nodes was 56 to 64 Gy, depending on extranodal
extension or close surgical margins. Patients
with gross residual disease or positive resection
margins received a total of 66 to 70 Gy to the
sites of residual disease.
Concurrent Chemoradiotherapy. Patients who did
not achieve a histologic complete response
(HCR) but had partial (>50% reduction of the
primary tumor) following IC were treated with
chemoradiotherapy. Definitive radiotherapy
began within 3 weeks after IC. The targets
included the primary tumor, grossly involved
lymph nodes, and electively treated nodes at
risk. Treatment was administered once daily, 5
days per week, at 2 Gy per fraction. Doses to
elective targets were 50 to 60 Gy, and the dose
to tumor and grossly involved lymph nodes was
a total of 70 Gy. Patients received cisplatin 100
mg/m2 or carboplatin (AUC ¼ 6) on days 1, 22,
and 43 concurrent with radiation with appropri-
ate dose modifications for neutropenia, grade 2
sensory neuropathy, or other grade 3 toxicities.
Eight weeks after the completion of chemora-
diotherapy, tumor evaluation was performed
with both a CT scan of the neck and direct lar-
yngoscopy. Patients with no residual disease at
the primary site were eligible for 2 cycles of ad-
juvant chemotherapy (cisplatin/carboplatin and
5-fluorouracil).
Statistical Methods. Chi-square statistics were
used to compare the frequency distribution of IC
response and clinical characteristics. Kaplan–
Meier analysis of survival endpoints included
overall survival, cause-specific survival, disease-
free survival, and laryngectomy-free survival.
Overall survival considered all deaths as events.
Cause-specific survival defined an event as head
and neck cancer-related death. Disease-free sur-
vival was defined as the time to recurrence. Lar-
yngectomy-free survival was defined as the time
to laryngectomy, recurrence, or death. The me-
dian follow-up was 45.1 months (95% CI: 39.6–
48.5). No subset analysis was planned.
The trial was designed to accrue 72 eligible
patients in order to meet our objectives of
assessing local control and voice-related quality
of life (V-RQOL). The sample size would have
been adequate to detect a 15% change in local
control and a 15 unit increase in V-RQOL with
80% power compared to our previously pub-
lished long term phase II study results.2 An
early termination rule was developed to stop the
trial if too many of the histologic complete res-
ponders required surgery or RT at the time of
the follow-up planned endoscopy or at the end of
their total course of chemotherapy.
RESULTS
Patient Characteristics. Between November 1,
2002, and December 31, 2004, 33 patients were
enrolled, of whom 32 were eligible. One patient
was not eligible due to a second primary cancer
diagnosed prior to treatment. Patient character-
istics are listed in Table 1. A total of 20% of
patients required pretreatment tracheostomy. A
total of 69% were stage IV, and of these 73%
had N2 or N3 disease. Accrual was stopped at
33 patients due to the trial’s early termination
criteria.
Response of the Primary Site to Induction Chemo-
therapy. Thirty-two patients received IC. Four
patients (13%) had a complete histologic and
clinical response (CR) and received chemother-
apy alone, 24 patients (75%) had partial
response (PR) and went on to concurrent chemo-
radiation, and 4 patients (13%) had <50%
response (nonresponders). All patients pro-
ceeded on the protocol as originally planned
with the exception of 1 nonresponder who
refused laryngectomy surgery and underwent
chemoradiotherapy.
Regional Failure Rate and Neck Dissection. None
of the 4 patients who were histologic CRs to
induction chemotherapy and treated with chem-
otherapy alone, were disease-free at the comple-
tion of chemotherapy. Moreover, all experienced
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failure in the neck (3 had persistent disease,
and 1 had local-regional progression), and all 4
received salvage therapy. Depending on the pri-
mary treatment, it could include surgery or sur-
gery combined with radiation. The addition of
radiation or chemoradiation was based on the
number of nodes in the neck, presence of extrac-
apsular spread, and whether the patient could
tolerate additional chemotherapy or radiation.
This varied by patient and only guidelines could
be established.
Of these patients, 2 had hypopharyngeal
(T4N2 and T3N1) and 2 had supraglottic (T2N2
and T3N0) primaries. Three had clinically posi-
tive nodal disease pretreatment. These 3
patients experienced persistence or progression
of their disease in the neck while undergoing
chemotherapy. Two of the 3 underwent salvage
neck dissection and received chemoradiotherapy
based on the presence of multiple positive nodes
or extracapsular extension. The third failed
locally and regionally after 5 cycles of chemo-
therapy for a supraglottic T3N0 cancer and
elected to undergo radiation therapy rather
than salvage surgery. This patient’s disease per-
sisted in the laryngeal cartilage after completing
hyperfractionated radiation and the patient sub-
sequently underwent salvage surgery with total
laryngectomy and extended neck dissection.
Direct extension of disease invading the carotid
artery was found, and the patient subsequently
sustained a carotid hemorrhage resulting in
death. The fourth complete responder developed
neck recurrence 2 months following the comple-
tion of definitive chemotherapy. This patient
underwent salvage neck dissection with postop-
erative radiation and remained alive without
disease.
In summary, all 4 of the patients who failed
chemotherapy alone, received postoperative in-
tensity-modulated radiation therapy as a part of
their salvage. Doses ranged from 66 to 74 Gy
delivered to high-risk volumes (positive mar-
gins, extracapsular nodal extensions found in
neck dissection, or prechemotherapy extents of
the gross disease), at 2 Gy/fractions, while the
rest of the bilateral neck received 50 to 64 Gy
concomitantly.
Of the patients with PR who were treated
with chemoradiation, 6 of 24 had locoregional
failures. Of those with PR and regional failures,
2 had persistent disease following chemoradia-
tion and the third had a recurrence 6 months af-
ter completion of treatment.
A total of 15 patients (47%) underwent neck
dissections. Three neck dissections were per-
formed with total laryngectomy after nonres-
ponse to induction chemotherapy. Five were
performed as planned neck dissections based on
pretreatment nodes >3 cm. Of these, 2 of 5
(40%) had positive disease on final pathology.
Four neck dissections were performed with lar-
yngectomy for primary salvage, 2 for progres-
sion of disease during treatment, and 1 for
regional recurrence.
Survival. The medium follow-up time for this
study was 45.1 months (95% CI, 39.6–48.5).
Kaplan–Meier overall survival estimate at 3
years was 67.6% (Figure 2A). Disease-specific sur-
vival estimate at 3 years was 78.1% (Figure 2B).
For the 4 with CRs after induction chemotherapy,
only 1 of 4 (25%) was alive at 3 years. Of the
others, 1 died from a carotid blowout following
surgical salvage, 1 from distant metastases, and
1 from regional recurrence. Overall, a total of 6
patients died from disease and 4 died from other
causes (carotid blowout, acute myelocytic leuke-
mia, congestive heart failure and sepsis, and
Table 1. Patient characteristics.
No. of patients
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myocardial infarction). Excluding the 4 complete
responders treated with chemotherapy alone, the
overall survival estimate at 3 years was 74.5%
(95% CI, 53.4% to 87.0%). Absence of recurrence
or second primary cancer at 3 years was 70.7%
for the entire cohort (Figure 2C).
Pattern of Recurrence. Regional failures
occurred in 7 patients, 4 in the chemotherapy-
only group and 3 in the chemoradiation group.
Of the 3 regional failures in the chemoradiation
group, 2 were unresectable in the neck. All
patients who were nonresponders to IC survived
and are disease-free. Three underwent laryngec-
tomy and 1 who refused surgery received suc-
cessful chemoradiation. Overall local control
estimate at 3 years with this treatment strategy
was 70.7% (Figure 2D). Three patients were
never free from disease.
Larynx Preservation. Larynx preservation at 3
years was achieved in 78% overall. Seven
patients underwent total laryngectomy. Three
patients underwent laryngectomy after nonres-
ponse to 1 cycle of IC, 2 patients had persistent
disease, and 2 patients had a local recurrence.
Two patients required laryngectomy but were
found to have unresectable disease in the oper-
ating room. One patient died in hospice from a
local recurrence within the larynx. Eighteen of
32 patients were alive with an intact larynx at 3
years. Functional results showed that of the
patients alive with intact larynx, 2 have trache-
ostomies and 1 is gastric-tube dependent. There-
fore, 16 patients were alive at 3 years with a
functional pharyngolarynx.
Toxicity and Complications. Common grade 2 to
4 toxicities are reported in Table 2. No grade 5
toxicities occurred. Overall, a total of 11 acute
and long-term complications occurred in 6
patients, consisting of carotid blowout (n ¼ 1),
chondroradionecrosis (n ¼ 3), persistent trache-
ostomy (n ¼ 2), persistent feeding tube (n ¼ 2),
FIGURE 2. (A) Overall survival estimate. (B) Disease-specific survival estimate. (C) Time to recurrence or secondary primary.
(D) Local control estimate. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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peripheral neuropathy (n ¼ 2), and aspiration
pneumonia (n ¼ 1).
DISCUSSION
In this study, treatment with chemotherapy
alone failed to control metastatic regional dis-
ease in patients achieving a HCR of their pri-
mary tumor. This finding suggests that the
biology and chemosensitivity of a primary tumor
may differ significantly between the primary tu-
mor and metastases. This finding was also noted
in the VA larynx trial when tumor response at
the primary and the neck were separately
assessed. A mixed response was noted almost
50% of the time. In our prior neoadjuvant stud-
ies, both greater and lesser responses in neck
nodes were observed with equal frequency com-
pared with the primary site. The risk of neck
failure is likely dependent on the presence of
apparent or occult regional disease with higher
risk for primary sites that have high rates of
metastases. The failures of the chemotherapy-
alone approach in this trial occurred in patients
with primary tumors of the hypopharynx or
supraglottic larynx, both sites associated with
high-risk of regional metastatic disease. Thus,
it may be particularly important to include a
surgical neck management strategy in such
patients.
Patient accrual into the study was termi-
nated early based on our stopping rule which
was reached due to regional failures requiring
radiation in our chemotherapy-only group which
would likely eliminate any chance of overall
improvement in voice functioning. Based on
these results, future attempts at chemotherapy-
alone treatment might consider early neck dis-
section as part of the treatment protocol for
Table 2. Chemotherapy toxicities.
Grade 2 Grade 3 Grade 4
After induction chemotherapy
Anemia 4 0 0
Chemo mucositis 14 4 0
ChemoXRT induced mucositis 0 1 0
Diarrhea 2 1 0
Fatigue/weakness 5 0 0
Leukopenia 1 3 0
Nausea 6 3 1
Neutropenia 2 3 1
Thrombocytopenia 0 1 0
Vomiting 5 3 1
During chemoradiation
Anemia 4 1 0
Chemo mucositis 2 0 0
ChemoXRT induced mucositis 8 5 0
Fatigue/weakness 10 1 0
Leukopenia 2 3 0
Nausea 5 5 0
Neuropathy 2 1 0
Neutropenia 3 3 0
Radiation dermatitis 10 0 0
Thrombocytopenia 4 1 0
Vomiting 4 5 0
After adjuvant therapy
Chemo mucositis 2 0 0
Diarrhea 0 1 0
Fatigue/weakness 4 0 0
Leukopenia 2 0 0
Nausea 2 0 0
Neuropathy 2 0 0
Neutropenia 1 0 0
Radiation dermatitis 2 0 0
Vomiting 2 0 0
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patients with regional disease or at high risk of
occult metastases. Only 1 of the 4 patients in
the chemotherapy-alone group, failed at the pri-
mary site and this was a deep cartilage recur-
rence of an aryepiglottic fold primary that could
have been a direct extension from the meta-
static neck disease. This patient initially had N0
disease but developed needle biopsy–positive
neck disease that involved soft tissues of the
neck, carotid artery, and thyroid cartilage. It is
unclear if earlier neck dissection would have
prevented this recurrence.
Patients who rapidly achieve a complete
response to IC typically represent the most
favorable prognostic group. Due to the high rate
of regional failure in our trial, the overall long-
term survival in this usually favorable group
was lower than expected. These results suggest
that effective treatment for regional disease
must include an additional modality, possibly
early neck dissection or radiation. Treating the
primary laryngeal cancer with chemotherapy-
alone and regional disease with surgery might
avoid the toxic effects of radiation or allow a
reduced radiation dose with less morbidity and
improved functional outcomes. Another
approach for patients with the most responsive
tumors may be treatment with radiotherapy
alone or reduced doses of RT concurrent with
chemotherapy or targeted agents. In our study,
all 4 of the failures with chemotherapy-alone
received RT with or without chemotherapy to
the primary site as well as to regional lymph
nodes. However, we were able to deliver less in-
tensive doses of radiotherapy to all but 1 of
these patients, which ultimately reduced the
morbidity related to full-dose radiation.
Overall, the chemotherapy regimen was well
tolerated by the patients. Repeated cycles (more
than 3) of platinum/5-fluorouracil–based therapy
may not be feasible in patients with head and
neck cancer. Thus, alternative regimens with
better tolerance are needed, hence our decision
to alternate weekly docetaxel with platinum and
5-fluorouracil. This allowed us to deliver up to 7
cycles of chemotherapy without treatment
delays, giving us the advantage of potentially
overcoming platinum resistance.
A chemotherapy-only strategy using the
agents currently available might be more effec-
tive in early stage patients, clinically node-nega-
tive patients, or those with a low risk of
regional disease. Our results differ significantly
from those reported by Laccourreye et al.5,6 In
their study, a subset of patients with early-stage
squamous cell carcinoma of the glottis amenable
to partial laryngeal surgery were treated with 3
cycles of induction chemotherapy. Five-year fol-
low-up revealed that patients with T1–3N0
tumors of the glottis who achieved a clinical and
HCR and were treated with additional chemo-
therapy alone, had a 95.2% 5-year survival rate,
70.7% local control rate, and 100% organ-preser-
vation rate including patients who received
salvage treatment.5 Local failures were success-
fully managed with surgery or RT for a 100%
local control rate after salvage treatment.
A subsequent study was expanded to include
T1–4N0 tumors which were not limited to the
glottis.6 Overall 5-year survival was 71.1%, 5-
year local control rate was 52.6%, and larynx
preservation was achieved in 89% after salvage
treatment. Interestingly, analysis of patients
with glottic carcinoma versus other sites in the
pharyngolarynx show a sharp difference between
the 2 groups, with an 85.1% and 54.8% 5-year
overall survival rate, respectively, and 65.7%
and 37.5% 5-year local control rates, respectively.
Our survival rates and rates of laryngeal preser-
vation in patients with much more advanced dis-
ease are comparable to these results.
Holsinger et al7 treated patients with T2–
T4aN0–N1 tumors which were amenable to resec-
tion by conservational laryngeal surgery in a sim-
ilar approach to Laccourreye et al.5,6 The majority
of the 30 evaluable patients had T2N0 disease.
Eleven patients (37%) had a pathologic complete
response after 3 to 4 cycles of chemotherapy using
paclitaxel, ifosfamide, and cisplatin. These
patients received 3 additional cycles of chemo-
therapy alone. None required a total laryngec-
tomy, but 1 required endoscopic conservational
laryngeal surgery following a local recurrence. Of
the 11 CRs, 4 were N1. None required neck dissec-
tion or had any evidence of regional recurrence.7
The survival rate reported in our current
study (68%) is slightly lower than previously
reported from our institution using induction
chemotherapy to select patients for chemoradia-
tion or laryngectomy. If patients receiving chem-
otherapy alone are excluded, the 3-year overall
survival estimate rises to 74.5%, which approxi-
mates our prior experience. Survival of patients
selected for surgery after less than a partial
response to a single course of neoadjuvant
chemotherapy was excellent, consistent with our
prior results. However, this represents an im-
portant subgroup that might benefit from newer
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targeted therapy or adjuvant approaches that
could result in organ preservation.
CONCLUSION
Using response to a single cycle of neoadjuvant
chemotherapy to identify and select patients for
organ preservation treatment approaches
achieves high survival and larynx preservation
rate in patients with advanced laryngeal cancer.
In the same population of advanced laryngeal
cancer, based on our results, it is not feasible to
control disease with chemotherapy alone, even
when planned neck dissections were part of the
original treatment plan. Furthermore, investiga-
tions to treat patients with laryngeal cancer
using chemotherapy or biologic agents should
most probably be reserved for those patients
with N0–1 nodal disease.
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